DB05828ExperimentalSmall molecule
LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. It acts at the Dopamine D4 receptors in the cortex and has... It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.
- Primary indication
- Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- LU-31130
Which companies are running trials of LU-31130, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account